Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-Th1 cytokine therapy

A method of diagnosing a clinical subtype of Crohn's disease having a superior or inferior clinical response to anti-Th1 cytokine therapy, comprising

• (a) determining whether SAPPA is present in a patient with CD and
• (b) determining the presence or absence of a TNFa10b4c1d3e3 haplotype in said patient with CD,
• wherein the presence of SAPPA in the absence of said TNFa10b4c1d3e3 haplotype indicates a clinical subtype of CD having a superior clinical response to anti-Th1 cytokine therapy and
• the presence of said TNFa10b4c1d3e3 haplotype in the absence of said SAPPA indicates a clinical subtype of CD having an inferior clinical response to anti-Th1 cytokine therapy.

A method of diagnosing a clinical subtype of Crohn's disease having a superior or inferior clinical response to anti-Th1 cytokine therapy, comprising

• (a) determining whether SAPPA is present in a patient with CD and
• (b) determining the presence or absence of a TNFa11b4c1d3e3 haplotype in said patient with CD,
• wherein the presence of SAPPA in the absence of said TNFa11b4c1d3e3 haplotype indicates a clinical subtype of CD having a superior clinical response to anti-Th1 cytokine therapy and
• the presence of said TNFa11b4c1d3e3 haplotype in the absence of said SAPPA indicates a clinical subtype of CD having an inferior clinical response to anti-Th1 cytokine therapy.

A method of diagnosing a clinical subtype of Crohn's disease having a superior or inferior clinical response to anti-Th1 cytokine therapy, comprising

• (a) determining whether SAPPA is present in a patient with CD;
• (b) determining the presence or absence of a TNFa10b4c1d3e3 haplotype in said patient with CD;
• and
• (c) determining the presence or absence of a TNFa11b4c1d3e3 haplotype in said patient with CD,
• wherein the presence of SAPPA in the absence of said TNFa10b4c1d3e3 and TNFa11b4c1d3e3 haplotypes indicates a clinical subtype of CD having a superior clinical response to anti-Th1 cytokine therapy,
• the presence of said TNFa10b4c1d3e3 haplotype in the absence of said SAPPA indicates a clinical subtype of CD having an inferior clinical response to anti-Th1 cytokine therapy and
• the presence of said TNFa11b4c1d3e3 haplotype in the absence of said SAPPA independently indicates a clinical subtype of CD having an inferior clinical response to anti-Th1 cytokine therapy.

A method of diagnosing a clinical subtype of CD having a superior or inferior clinical response to anti-Th1 cytokine therapy, comprising the steps of:

• (a) determining whether SAPPA is present in a patient with CD;
• (b) determining whether pANCA is present in said patient with CD;
• (c) determining the presence or absence of a TNFa10b4c1d3e3 haplotype in said patient with CD;
• (d) determining the presence or absence of a TNFa11b4c1d3e3 haplotype in said patient with CD;
• and
• (e) determining the presence or absence of the homozygous TNF-β 1111 haplotype at the TNFc, aa13L, aa26 and NcoI loci in said patient with CD,
• wherein the presence of SAPPA in the absence of said TNFa10b4c1d3e3, TNFa10b4c1d3e3 and TNF-β 1111 haplotypes is diagnostic of a clinical subtype of CD having a superior clinical response to anti-Th1 cytokine therapy,
• the presence of pANCA in the absence of said SAPPA is diagnostic of a clinical subtype of CD having an inferior clinical response to anti-Th1 cytokine therapy,
• the presence of said TNFa10b4c1d3e3 haplotype in the absence of said SAPPA independently is diagnostic of a clinical subtype of CD having an inferior clinical response to anti-Th1 cytokine therapy,
• the presence of said TNFa11b4c1d3e3 haplotype in the absence of said SAPPA independently is diagnostic of a clinical subtype of CD having an inferior clinical response to anti-Th1 cytokine therapy and
• the presence of said homozygous TNF-β 1111 haplotype in the absence of said SAPPA independently is diagnostic of a clinical subtype of CD having an inferior clinical response to anti-Th1 cytokine therapy.